Leveraging modeling and simulation to optimize the therapeutic window for epigenetic modifier drugs
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Leveraging modeling and simulation to optimize the therapeutic window for epigenetic modifier drugs
Authors
Keywords
Epigenetic drugs, Therapeutic window, Pharmacokinetic/pharmacodynamic, Modeling and simulation, Optimized dosing regimen, Clinical utility
Journal
PHARMACOLOGY & THERAPEUTICS
Volume -, Issue -, Pages 108162
Publisher
Elsevier BV
Online
2022-02-19
DOI
10.1016/j.pharmthera.2022.108162
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Free Drug Theory – No Longer Just a Hypothesis?
- (2022) Scott G. Summerfield et al. PHARMACEUTICAL RESEARCH
- Advances in epigenetic therapeutics with focus on solid tumors
- (2021) Ning Jin et al. Clinical Epigenetics
- IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
- (2021) Claudio Cerchione et al. Frontiers in Oncology
- Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies
- (2021) Sebastian Bauer et al. BRITISH JOURNAL OF CANCER
- How translational modeling in oncology needs to get the mechanism just right
- (2021) James W. T. Yates et al. CTS-Clinical and Translational Science
- Translational Pharmacokinetic-Pharmacodynamic Modeling for An Orally Available Novel Inhibitor of Epigenetic Regulator Enhancer of Zeste Homolog 2
- (2020) Shinji Yamazaki et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study
- (2020) Byung-Hyun Lee et al. Scientific Reports
- Tazemetostat: First Approval
- (2020) Sheridan M. Hoy DRUGS
- BET inhibitor molibresib for the treatment of advanced solid tumors: Final results from an open-label phase I/II study.
- (2020) Sophie Cousin et al. JOURNAL OF CLINICAL ONCOLOGY
- Physiologically-based pharmacokinetic models for children: Starting to reach maturation?
- (2020) Laurens F.M. Verscheijden et al. PHARMACOLOGY & THERAPEUTICS
- Understanding the Mechanisms by Which Epigenetic Modifiers Avert Therapy Resistance in Cancer
- (2020) Anthony Quagliano et al. Frontiers in Oncology
- Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology
- (2019) Rashmi R. Shah DRUG SAFETY
- Emerging epigenetic-modulating therapies in lymphoma
- (2019) David Sermer et al. Nature Reviews Clinical Oncology
- Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer
- (2019) Helai P. Mohammad et al. NATURE MEDICINE
- Predicting In Vivo Efficacy from In Vitro Data: Quantitative Systems Pharmacology Modeling for an Epigenetic Modifier Drug in Cancer
- (2019) Mehdi Bouhaddou et al. CTS-Clinical and Translational Science
- Clinical efficacy of the optimal biological dose in early-phase trials of anti-cancer targeted therapies
- (2019) Pauline Corbaux et al. EUROPEAN JOURNAL OF CANCER
- LSD1/KDM1A inhibitors in clinical trials: advances and prospects
- (2019) Yuan Fang et al. Journal of Hematology & Oncology
- The timeline of epigenetic drug discovery: from reality to dreams
- (2019) A. Ganesan et al. Clinical Epigenetics
- Pediatric Dose Selection and Utility of PBPK in Determining Dose
- (2018) Ian E. Templeton et al. AAPS Journal
- ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia
- (2018) Tamara Maes et al. CANCER CELL
- Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy
- (2018) Subhankar Biswas et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)
- (2017) Pei-Pei Kung et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines
- (2017) Marielle Dejligbjerg et al. Cancer Biomarkers
- ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma
- (2016) C. L. Batlevi et al. HAEMATOLOGICA
- Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
- (2016) Miro J. Eigenmann et al. MOLECULAR CANCER THERAPEUTICS
- Epigenetic Determinants of Cancer
- (2016) Stephen B. Baylin et al. Cold Spring Harbor Perspectives in Biology
- Epigenetics in Cancer: A Hematological Perspective
- (2016) Maximilian Stahl et al. PLoS Genetics
- ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma
- (2016) C. L. Batlevi et al. HAEMATOLOGICA
- Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example
- (2015) J. R. Sachs et al. CLINICAL CANCER RESEARCH
- Epigenetic therapy for solid tumors: from bench science to clinical trials
- (2015) Yen-Yi Juo et al. Epigenomics
- Epigenetic drugs against cancer: an evolving landscape
- (2014) Antonella Di Costanzo et al. ARCHIVES OF TOXICOLOGY
- Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients
- (2014) Quentin Chalret du Rieu et al. INVESTIGATIONAL NEW DRUGS
- Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia
- (2014) Regina García-Delgado et al. LEUKEMIA RESEARCH
- Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
- (2014) David Cook et al. NATURE REVIEWS DRUG DISCOVERY
- Model-based drug discovery: implementation and impact
- (2013) Sandra A.G. Visser et al. DRUG DISCOVERY TODAY
- Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms
- (2013) A Ali et al. Cell Death & Disease
- In Epigenetic Therapy, Less Is More
- (2012) Hui Shen et al. Cell Stem Cell
- Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival
- (2011) Paul Morgan et al. DRUG DISCOVERY TODAY
- Scaling Pharmacodynamics from In Vitro and Preclinical Animal Studies to Humans
- (2009) Donald E. Mager et al. Drug Metabolism and Pharmacokinetics
- Vorinostat in solid and hematologic malignancies
- (2009) David Siegel et al. Journal of Hematology & Oncology
- Modeling of tumor growth and anticancer effects of combination therapy
- (2009) Gilbert Koch et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now